Dr. Andrew DeBlase, Purdue University
If the infrared spectrum gives us a “fingerprint” of the molecule, why then is it not used more regularly to determine structure? I will describe several experimental methods that I have helped to develop as a Ph.D. student and a postdoctoral researcher to glean detailed structural insight using IR and UV spectroscopy.
“Design and Synthesis of Mitochondrial Citrate Carrier Protein Inhibitors for Treating Lung Cancer AND Design and Synthesis of Inhibitors of Interleukin-1β Protein-Protein Interactions for the Treatment of Osteoarthritis”
Doctoral Candidate (Dr. Mikell Paige, advisor)
“Novel Processes to Quantify Protein in Visceral Adipose Tissue and Use to Evaluate Disease Pathogenesis”
Doctoral Candidate (Dr. Barney Bishop, advisor)
You’re here. Now it’s your time.
Join the College of Science in celebrating the start of the school year on Wednesday, September 6 from 12 – 5 p.m. throughout Exploratory Hall.
- Satisfy your appetite with some free food
- Find your squad with #MasonScience clubs and organizations
- Follow us on Facebook and/or Twitter to score a special giveaway
- Meet College of Science faculty and staff
- Discover your academic and career options
- Learn what resources are available to you
- Have fun with Human Bingo and even more giveaways
We can’t wait to see you there!
Introduction to the semester’s seminar series, by Dr. Young-Ok You.
“The Sphingosine-1-phosphate pathway: Sphingosine kinase as a drug target”
Dr. Webster Santos (Virginia Tech)
Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule that interacts with its five G-protein coupled receptors (S1P1–5) to regulate cell growth and survival and has been implicated in a variety of diseases including cancer, fibrosis, inflammation, neurodegenerative diseases, and sickle cell disease. As the key mediators in the synthesis of S1P, sphingosine kinase (SphK) isoforms 1 and 2 have attracted attention as viable targets for pharmaceutical inhibition. In this presentation, I will discuss our efforts in inhibiting SphK through extensive medicinal chemistry campaigns. The activity of inhibitors in mice as well as their therapeutic implications will be discussed.
Please email Dr. You at email@example.com if you’d like to meet the speaker.